Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase 3

Terminated

Conditions: Stage IIIA Non-Small Cell Lung Cancer
Stage IV Non-Small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma
Stage IIIB Non-Small Cell Lung Cancer

Interventions: Drug: Pemetrexed Disodium
Drug: Erlotinib Hydrochloride

First Posted Date: 2008-08-21

Last Posted Date: 2015-10-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 23

Registration Number: NCT00738881

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Sparks Regional Medical Center, Fort Smith, Arkansas, United States
🇺🇸
Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States

and more 265 locations

Assessment of Beta Cell Mass by PET Scans With [11C] Dihydrotetrabenazine (DTBZ) in Longstanding Type 1 Diabetes.

Completed

Conditions: Type 1 Diabetes

First Posted Date: 2008-08-21

Last Posted Date: 2014-09-25

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 18

Registration Number: NCT00738907

High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1

Phase 2

Completed

Conditions: Chronic Hepatitis C

First Posted Date: 2008-08-15

Last Posted Date: 2014-10-20

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 21

Registration Number: NCT00735969

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions: Drug: saracatinib
Other: pharmacogenomic studies
Other: pharmacological study
Procedure: positron emission tomography
Radiation: fludeoxyglucose F 18
Other: laboratory biomarker analysis

First Posted Date: 2008-08-15

Last Posted Date: 2019-04-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT00735917

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
University of Colorado at Denver, Aurora, Colorado, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

and more 6 locations

Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Anemia
Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia
Prolymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma
Thrombocytopenia

Interventions: Drug: Alvocidib Hydrochloride
Drug: Lenalidomide
Other: Pharmacological Study
Other: Laboratory Biomarker Analysis

First Posted Date: 2008-08-15

Last Posted Date: 2015-04-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 39

Registration Number: NCT00735930

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Physical Therapy in Women With Interstitial Cystitis

Not Applicable

Completed

Conditions: Interstitial Cystitis
Painful Bladder Syndrome

Interventions: Other: Global Therapeutic Massages (GTM)
Other: Myofascial Tissue Manipulation (MTM)

First Posted Date: 2008-08-13

Last Posted Date: 2021-03-22

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 81

Registration Number: NCT00733603

Locations: 🇺🇸
Univeristy of California San Diego, San Diego, California, United States
🇺🇸
Stanford University Medical center, Stanford, California, United States
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States

and more 8 locations

Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1

Completed

Conditions: Adult Gliosarcoma
Adult Giant Cell Glioblastoma
Adult Glioblastoma

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Procedure: Cognitive Assessment
Other: Laboratory Biomarker Analysis
Drug: Temozolomide
Drug: Vorinostat

First Posted Date: 2008-08-11

Last Posted Date: 2022-08-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 125

Registration Number: NCT00731731

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
UCSF Medical Center-Parnassus, San Francisco, California, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

and more 107 locations

Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Carcinoma
Recurrent Uterine Corpus Carcinoma
Stage IIIA Uterine Corpus Cancer
Stage IIIB Uterine Corpus Cancer
Stage IIIC1 Uterine Corpus Cancer
Stage IIIC2 Uterine Corpus Cancer
Stage IVA Uterine Corpus Cancer
Stage IVB Uterine Corpus Cancer

Interventions: Other: Laboratory Biomarker Analysis
Drug: Megestrol Acetate
Drug: Temsirolimus
Drug: Tamoxifen Citrate

First Posted Date: 2008-08-07

Last Posted Date: 2019-07-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 73

Registration Number: NCT00729586

Locations: 🇺🇸
Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States
🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸
University of California San Diego, San Diego, California, United States

and more 105 locations

Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

Phase 2

Completed

Conditions: Stage III Thyroid Gland Follicular Carcinoma
Stage IV Thyroid Gland Follicular Carcinoma
Recurrent Thyroid Gland Carcinoma
Stage III Thyroid Gland Papillary Carcinoma
Stage IV Thyroid Gland Papillary Carcinoma

Interventions: Radiation: Fludeoxyglucose F-18
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Procedure: Positron Emission Tomography
Biological: Ziv-Aflibercept

First Posted Date: 2008-08-07

Last Posted Date: 2017-03-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 41

Registration Number: NCT00729157

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

A Trial of Two Diets for Weight and Diabetes Management

Not Applicable

Completed

Conditions: Type 2 Diabetes Mellitus
Obesity

Interventions: Behavioral: Lifestyle Modification

First Posted Date: 2008-08-07

Last Posted Date: 2011-02-01

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 80

Registration Number: NCT00729196

Locations: 🇺🇸
University of Pennsylvania, Center for Weight and Eating Disorders, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy